NewEdge Advisors’s UroGen Pharma URGN Stock Holding History

NewEdge Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.68K	Hold	100	–	–	﹤0.01%	3803
2026 Q1	$1.8K	Hold	100	–	–	﹤0.01%	3824
2025 Q4	$2.34K	Hold	100	–	–	﹤0.01%	3855
2025 Q3	$2K	Hold	100	–	–	﹤0.01%	3781
2025 Q2	$1.37K	Buy	+100	New	+$960	﹤0.01%	3680

Other funds holding URGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's URGN Position: Q2 2026 in Review

NewEdge Advisors held its UroGen Pharma (URGN) position steady in Q2 2026 at 100 shares worth $3.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3803.

NewEdge Advisors first reported a position in URGN in Q2 2025 and has held it in 5 quarters since. 120 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

NewEdge Advisors held 100 shares of UroGen Pharma worth $3.68K as of Q2 2026.
NewEdge Advisors left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3803 holding.
NewEdge Advisors first reported a position in UroGen Pharma in Q2 2025 and has held it in 5 quarters since.
120 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.